Table 2.
Multivariate analysis (generalized linear model): factors associated with the overall cost (costs include antiretroviral regimens and hospitalizations and non-antiretroviral treatments)
| Characteristics | Patients who did not switch during follow-up: persistence =100% (N=309)
|
Patients who switched during follow-up: persistence <100% (N=165)
|
All patients
|
|||
|---|---|---|---|---|---|---|
| Adjusted* mean cost (SE), euros | P-value | Adjusted* mean cost (SE), euros | P-value | Adjusted* mean cost (SE), euros | P-value | |
| CD4+, cells/μL | ||||||
| ≤200 | 15,600 (1,377) | 0.0034 | 20,260 (3,196) | 0.095 | 17,232 (1,407) | 0.0008 |
| 201–350 | 11,594 (1,231) | 15,665 (3,357) | 12,832 (1,320) | |||
| 351–500 | 12,365 (1,365) | 12,564 (3,196) | 12,416 (1,388) | |||
| >500 | 13,059 (1,708) | 14,607 (3,867) | 13,924 (1,735) | |||
| First-line regimen | ||||||
| STR | 11,161 (1,353) | <0.0001 | 13,973 (3,851) | 0.261 | 12,096 (1,440) | 0.0001 |
| MTR | 15,148 (1,186) | 17,575 (2,455) | 16,106 (1,174) | |||
Note:
*
Adjusted for age, sex, anti-HCV Ab, HIV risk factor, baseline HIV-RNA.
Abbreviations: CD4, cluster of differentiation 4; MTR, multi-tablet regimen; SE, standard error; STR, single-tablet regimen; anti-HCV Ab, antibodies anti-HCV.